The way I see it is that PAUL has been buying CytoDyn for investments for their clients. More than 32 million dollars of transactions since December. What is very interesting is that they are now accumulating shares in ENZC and ENZC also has a solution for the treatment of HIV. They do like disruptive bio companies that have a solid management team and proven technology.
News 
Market Data 
Discover 
